GRIN powers HNF’s patient-centered research and drug discovery initiatives.

by | Apr 15, 2020 | 2 comments

The Global Registry for Inherited Neuropathies (GRIN) powers the Hereditary Neuropathy Foundation’s patient-centered research and drug discovery initiatives. Leading Charcot-Marie-Tooth advocacy organization’s innovative platform plays a critical role in its mission.

Our registry, GRIN, has been central to our patient centered research initiatives for over 6 years. The ability to have real-time access to important patient reported natural history data has been a game changer for HNF’s research, industry and academic partners. Originally hosted using 3rd party software, in 2019 HNF migrated GRIN onto our own IRB approved, HIPAA compliant platform. Built to our own specifications, GRIN allows us to quickly analyze data to uncover insightful correlations between genotypes, phenotypes, comorbidities and other important patient data.

GRIN has played a critical role in identifying important issues related to the CMT patient experience, revealing new areas to explore and research. When pain was noted by 65% of patients with inherited neuropathies, HNF quickly sprang into action, hosting a dedicated summit on patient pain in 2017, as well as advocating for pain scales to be considered as a secondary endpoint for clinical trials. “Without real time access to this critical data point, we wouldn’t have been able to demonstrate the importance of this issue to our industry and research partners,” says Joy Aldrich, HNF’s Patient Advocacy Director. “GRIN also helped us effectively convey the CMT patient’s disease experience for our Externally-led, Patient Focused Drug Discovery meeting with the FDA in 2018.”

GRIN has also facilitated recruitment for the latest clinical trials by pinpointing ideal candidates with speed and accuracy. Future innovations for the platform include an interactive patient portal, the integration of de identified data with other partner consortiums, and the collection of longitudinal patient data. GRIN also supports the CMT&Me app, sponsored by Pharnext, by identifying patients that are willing to participate in that important digital lifestyle study

To participate and accelerate research, join GRIN. www.hnf-cure.org/registry 

Contact: Allison Moore [email protected]

 

 

Learn more on this topic

Related Blog Posts

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Hot off the press

Some recent papers on Charcot-Marie-Tooth (CMT) disease go to show that we are steadily and impressively peeling back the complexity of the biology even though it is a relatively common rare disease with several thousand publications on it.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

HNF and Wave Skater form a Partnership

I (Allison Moore)  is amazed how life moves in such wondrous ways. My family has the good fortune to spend summers at a beautiful Long Island beach where my husband and boys enjoy riding the waves on boogie boards.

HNF-WVU-NIOSH Study update:

We are pleased to update our readers on the progress of the WVU-NIOSH study, “A Bi-Directional Translational Model of Exercise Training in the Treatment of Charcot-Marie-Tooth Disease”

Join the conversation

Leave a Comment

2 Comments

  1. Werner Walther

    I was prepared to fill in the GRIN regitry data.
    The form, however dropped me out and went back to the beginning.
    I feel, there is something wrong with entering data.

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news